At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 686 enrolled
Drug / intervention
IDP-126 Gel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% Adapalene/2.5% BPO), in the Treatment of Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating IDP-126 Gel, IDP-126 Vehicle Gel, and 1 other intervention for Acne Vulgaris. Completed, enrolled 686 participants across 42 sites in 3 countries.
Detailed Summary
The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesBelgium, Canada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJun 2021
Primary CompletionSep 2022
TodayJul 2026
First PostedMay 19, 2021
Enrollment StartJun 11, 2021
Primary CompletionSep 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.1 years ago
Interventions
IDP-126 Geldrug
Gel applied to face once daily in the evening.
IDP-126 Vehicle Geldrug
Gel applied to face once daily in the evening.
Epiduo® Forte Geldrug
Gel applied to face once daily in the evening.